BJH - volume 8, issue Abstract Book BHS, february 2017
S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, J. Alexis Ruiz , M. Roos , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
D. Bron MD, PhD, A. Salaroli MD, N. Meuleman MD, PhD, M. Maerevoet MD, M. Vercruyssen MD, C. Spilleboudt MD, A. De Wind MD, PhD, G. Dapri , G.B. Cadiere , B. Cadiere
BJH - volume 8, issue Abstract Book BHS, february 2017
L. Sattar , M. Maerevoet MD, D. Bron MD, PhD, B. Cantinieaux , P. Hermans MD, PhD, T. Pepersack MD, PhD
BJH - volume 8, issue 1, february 2017
M. Maerevoet MD
ASH 2016 again featured a plethora of abstracts dedicated to lymphoma. In this summary we will discuss the studies that, in our opinion, have the highest relevance for daily clinical practice. This summary will not address indolent lymphoma as this will be covered in another article in this ASH special.
(BELG J HEMATOL 2017;8(1):10–3)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, A. Etienne , C. Reynaert , D. Razavi MD, PhD, D. Bron MD, PhD
BJH - volume 6, issue 4, october 2015
D. Bron MD, PhD, M. Maerevoet MD
Phosphoinositide 3-kinase inhibitors represent a new group of promising targeted therapies for malignant hemopathies and primarily lymphoproliferative disorders. This short report summarises recent knowledge on the mechanism of action, the rationale to use it in humans bearing malignant hemopathies and preliminary clinical trials’ data that led to the Food and Drug Administration approval of one of these compounds (idelalisib).
(BELG J HEMATOL 2015;6(4): 152–5)
Read moreBJH - volume 6, issue 1, march 2015
M. Maerevoet MD, J. Vouriot MD, N. Meuleman MD, PhD, D. Bron MD, PhD
Diffuse large B-cell lymphoma is a frequent pathology in older individuals, and though curable by R-CHOP 21, treatment toxicity increases in frail patients. Therefore, therapeutic choices have to take into account Comprehensive Geriatric Assessment in addition to Performance Status, but reliable and standardised clinical decision-making tools are sorely lacking. However, Mabthera-containing treatments adapted for frail patients and co-morbidities can be used with a satisfactory survival rate at two years. Nevertheless, the main cause of death remains disease progression.
(BELG J HEMATOL 2014;6(1):4–9)
Read more
Top
